ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma
April 06, 2021Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, today announced that the ... -
Antengene announces China’s NMPA approval for IND application for ATG-019 clinical trial
April 06, 2021Antengene has announced that China’s National Medical Products Administration (NMPA) has given approval to investigational new drug (IND) application for Phase I clinical trials of ATG-019 (monotherapy or combined with niacin ER) in patients with ...
Pharma Sources Insight January 2025
